Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs
- 25 July 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (16) , 1085-1092
- https://doi.org/10.1038/sj.gt.3301734
Abstract
Genetic modification of human lymphocytes is being employed in strategies to correct enzyme deficiencies, encode cytokines and to redirect lymphocytes to antigenic targets other than those encoded by their endogenous T cell receptor. However, expression of transgenes in primary lymphocytes is generally low. Reasoning that vector modification may lead to increased transgene expression and subsequent increases in function, we have performed two retroviral vector modifications and report their effect on the functional expression in primary lymphocytes. A chimeric receptor specific for the colon carcinoma-associated antigen, EGP40, was initially incorporated into the retroviral vector LXSN. In this vector, receptor expression is driven by the Moloney murine leukemia virus LTR, and neomycin phosphotransferase expression driven by the SV40 promoter. Replacement of SV40 with an internal ribosomal entry site (IRES) increased the transgene activity of a mouse T cell line and human PBL as judged by increased cytokine release in response to antigen positive target cells. A further increase in transgene function was generated by the additional incorporation of a splice acceptor motif into the construct. Human PBL transduced with vector incorporating both IRES and intron were consistently more effective at lysing antigen positive colorectal carcinoma cells.Keywords
This publication has 27 references indexed in Scilit:
- Recognition of human colon cancer by T cells transduced with a chimeric receptor geneCancer Gene Therapy, 2000
- Improvement of Retroviral Packaging Cell Lines by Introducing the Polyomavirus Early RegionHuman Gene Therapy, 1998
- The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytesGene Therapy, 1997
- Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44V6-specific SCFV: ζ-chimeraInternational Journal of Cancer, 1996
- Improved Gene Transfer into Human Lymphocytes Using Retroviruses with the Gibbon Ape Leukemia Virus EnvelopeHuman Gene Therapy, 1996
- T Cell Activation Determined by T Cell Receptor Number and Tunable ThresholdsScience, 1996
- T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 YearsScience, 1995
- High-Level Expression from a Cytomegalovirus Promoter in Macrophage CellsHuman Gene Therapy, 1995
- Upregulation of Tumor Necrosis Factor-α Production by Retrovirally Transduced Human Tumor-Infiltrating Lymphocytes Using trans-Retinoic AcidCellular Immunology, 1994
- The Development of Gene Therapy for the Treatment of CancerAnnals of Surgery, 1993